Evidence map›Paper›PMID 38438841›Full record

ArticleBMC cancer2024

MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.

Sébastien Molière, Massimo Lodi, Suzanne Leblanc, Anne Gressel, Carole Mathelin, Fabien Alpy, Marie-Pierre Chenard, Catherine Tomasetto

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sébastien MolièreInstitute of Genetics and Molecular and Cellular Biology, Illkirch, France. sebastien.moliere@chru-strasbourg.fr.
Massimo LodiInstitute of Genetics and Molecular and Cellular Biology, Illkirch, France.
Suzanne LeblancGroupe Rhénan de Pathologie, Schiltigheim, France.
Anne GresselDepartment of Pathology, Strasbourg University Hospital, Hôpital de Hautepierre, Avenue Molière, Strasbourg, France.
Carole MathelinUniversity of Strasbourg, Illkirch, France.
Fabien AlpyInstitute of Genetics and Molecular and Cellular Biology, Illkirch, France.
Marie-Pierre ChenardUniversity of Strasbourg, Illkirch, France.
Catherine TomasettoInstitute of Genetics and Molecular and Cellular Biology, Illkirch, France.
Centre National de la Recherche Scientifique · FRHôpital d'Hautepierre · FRInstitut de Cancérologie Strasbourg · FRInstitut de génétique et de biologie moléculaire et cellulaire · FR

Funding

Alsace Contre le Cancer Alsace Contre le CancerEUR IMCBio ANR-17-EURE-0023IdEx Unistra ANR-10-IDEX-0002Ligue Contre le Cancer Ligue Contre le CancerSEVE (Sein et Vie) SEVE (Sein et Vie)
6 · The paper itself

Abstract

backgroundEarly hormone-positive breast cancers typically have favorable outcomes, yet long-term surveillance is crucial due to the risk of late recurrences. While many studies associate MMP-11 expression with poor prognosis in breast cancer, few focus on early-stage cases. This study explores MMP-11 as an early prognostic marker in hormone-positive breast cancers.

methodsIn this retrospective study, 228 women with early hormone-positive invasive ductal carcinoma, treated surgically between 2011 and 2016, were included. MMP-11 expression was measured by immunohistochemistry, and its association with clinical and MRI data was analyzed.

resultsAmong the patients (aged 31-89, median 60, with average tumor size of 15.7 mm), MMP-11 staining was observed in half of the cases. This positivity correlated with higher uPA levels and tumor grade but not with nodal status or size. Furthermore, MMP-11 positivity showed specific associations with MRI features. Over a follow-up period of 6.5 years, only 12 oncological events occurred. Disease-free survival was linked to Ki67 and MMP-11.

conclusionMMP-11, primarily present in tumor-surrounding stromal cells, correlates with tumor grade and uPA levels. MMP-11 immunohistochemical score demonstrates a suggestive trend in association with disease-free survival, independent of Ki67 and other traditional prognostic factors. This highlights the potential of MMP-11 as a valuable marker in managing early hormone-positive breast cancer.

Indexed as

Breast NeoplasmsDisease-Free SurvivalFemaleHormonesHumansKi-67 AntigenMagnetic Resonance ImagingMatrix Metalloproteinase 11Retrospective StudiesHormonesKi-67 AntigenMatrix Metalloproteinase 11Breast cancerBreast MRIImmunohistochemistryMicroenvironmentMMP-11Recurrence

Identifiers

PMID38438841
PMCPMC10913243
OpenAlexW4392382024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.